Journal of Clinical & Experimental Pathology
Open Access

Abstract

Background: In recent years, relationship between some molecular markers and clinicopathological parameters, which have prognostic importance in prostate carcinoma (PCa) was investigated and new treatment protocols were developed. In the present study it is aimed to determine expressions of LC3A, NGEP and hepsin and to evaluate their associations with clinicopathologic prognostic parameters in PCa. Materials & Methods: The present study comprised 51 PCa patients who underwent radical prostatectomy between January 2010 and March 2014 in our institute. Clinical data were obtained from patients’ clinical records. Hematoxylin eosin stained slides were used to assess pathological prognostic parameters such as Gleason score, tumor stage, tumor volume, capsule invasion, lymphovascular invasion, perineural invasion and seminal vesicle invasion. Immunoreactivity scoring system (IRS) was used to determine NGEP, LC3A and hepsin expressions. Results: NGEP and LC3A expressions were found to be higher in carcinoma and HPIN foci than benign prostate tissue and both were highest in HPIN foci. Hepsin expression did not differ between benign prostate tissue, HPIN or carcinoma foci. No significant relationship was determined between LC3A and NGEP expressions and clinicopathological parameters, however; low hepsin expression was found to be associated with capsule invasion. Conclusions: We suggest that NGEP, LC3A and hepsin are promising to be targeted immunotherapy in PCa treatment due to their different expressions between benign prostate tissue, HPIN and carcinoma foci. But we also believe that further studies with larger series are needed for these molecules to be used as prognostic markers or a part of routine treatment modalities.

Biography

Zeliha Esin Celik was graduated from Selcuk University Faculty of Medicine in 2011. She has been working as a Lecturer at the same institute since 2013. She has done investigations about molecular markers on prostate and bladder carcinomas. She is a Member of Uropathology Working Group, Federation of Turkish Pathology Societies.

Email: dresincelik@hotmail.com